Relay Therapeutics to Participate in Upcoming Investor Conferences
Relay Therapeutics (Nasdaq: RLAY) has announced its participation in four upcoming investor conferences in November and December 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY) has announced its participation in four upcoming investor conferences in November and December 2024. The company will participate in fireside chats at the Guggenheim Healthcare Innovation Conference (Nov 13), Stifel Healthcare Conference (Nov 18), Jefferies London Healthcare Conference (Nov 20), and Citizens JMP Hematology and Oncology Summit (Dec 2). All sessions will be webcast live and accessible through Relay's website, with recordings available for 30 days after each event.
Details
News Market Reaction – RLAY
The recorded move for RLAY in the trading session of this news was +0.98%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in the following upcoming fireside chats:
- Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 10:00 a.m. ET
- Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 10:55 a.m. ET
- Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 6:30 a.m. ET (11:30 a.m. GMT)
- The Citizens JMP Hematology and Oncology Summit, taking place virtually on Monday, December 2, 2024 at 1:30 p.m. ET
The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Megan Goulart
617-545-5526
mgoulart@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.